Rumors of Exelixis Inc. hiring Goldman Sachs to prepare for possible sale offers sent shares of the South San Francisco cancer drug company higher, according to Bloomberg.
A spokesman for Exelixis (NASDAQ: EXEL) told Bloomberg that the company does not comment on such reports, noting that sale rumors have “been around the company for a long time.”
Exelixis, which had been known for its prodigious pipeline of drugs, has garnered lots of attention over the past five months because of a single drug. The company has opted to focus on XL-184, or cabozantinib, which appears to stop cancerous growth not only in soft tissue but also on bone.
No comments:
Post a Comment